Rupesh Raina, MD
Nephrology · Akron, OHNPI 1295939734
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $133,601 of the $162,728 with a category attached, or 82.1%. 17 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 36.9% of the total. Reporting peaked in 2019 at $68,310 and has fallen 99.6% since, to $258 in 2025. Among nephrology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 191 payments — averaging $851.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$60K
- Mallinckrodt Hospital Products Inc.$44K
- Mallinckrodt Enterprises LLC$29K
- Aurinia Pharma U.S., Inc.$13K
- Amgen$7K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$3K
- plus $6K from 11 others
Across 59 payments — averaging $2425.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Travere Therapeutics, Inc.$71K
- AMAG Pharmaceuticals, Inc.$24K
- AstraZeneca$20K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$14K
- Akebia Therapeutics Inc$11K
- Bayer$2K
- plus $2K from 1 others
What the payments were for
- Consulting fees$9,5506%
- Speaking & faculty fees$133,60182%
- Travel & lodging$14,6079%
- Food & beverage$4,6943%
- Education$2760%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 60 | $60,109 |
| Mallinckrodt Hospital Products Inc. | 36 | $43,645 |
| Mallinckrodt Enterprises LLC | 26 | $29,111 |
| Aurinia Pharma U.S., Inc. | 14 | $13,242 |
| Amgen(2 entities) | 14 | $6,743 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $3,400 |
| Novartis | 4 | $3,309 |
| Kaneka Medical America LLC | 1 | $1,500 |
| AstraZeneca | 10 | $593 |
| Travere Therapeutics, Inc. | 9 | $354 |
| GSK | 2 | $224 |
| Fresenius USA Marketing, Inc. | 6 | $180 |
| Vifor Pharma, Inc. | 4 | $169 |
| Inspire Medical Systems, Inc. | 1 | $94 |
| Bayer | 1 | $20 |
| Calliditas Therapeutics US Inc. | 1 | $18 |
| Nuwellis, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$162,728 in reported general payments places this provider in the 95th percentile of 450 nephrology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 25 | $92,951 |
| XphozahTenapanor Hcl | 21 | $77,411 |
| FarxigaDapagliflozin Propanediol | 62 | $53,396 |
| VeltassaPatiromer Calcium Sorbitex | 12 | $10,166 |
| Sevelamer Carbonate | 42 | $5,916 |
| Calcium Acetate | 37 | $2,718 |
| ProsolParenteral Amino Acid 20% No.1 | 12 | $1,904 |
| Clonidine | 12 | $1,684 |
| Bumetanide | 42 | $1,434 |
| Labetalol Hcl | 16 | $771 |
| Febuxostat | 12 | $634 |
| Potassium Chloride | 27 | $587 |
| Midodrine Hcl | 15 | $510 |
| Furosemide | 55 | $355 |
| Torsemide | 42 | $336 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $180 | $92,95125 claims |
| AstraZenecaFarxiga | $593 | $53,39662 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 450 nephrology providers in Ohio.
Other nephrology in Akron
- Preti ChaturvediAkron$11K
- Brad RovinColumbus$379K
- Nissreen ElfadawyChardon$327K
- Andrew LazarBeachwood$315K
- Amit GovilCincinnati$298K
- Georges NakhoulCleveland$255K
- Sankar NavaneethanCleveland$253K
- Ibrahim AhmadKettering$232K
- Prabir Roy ChaudhuryCincinnati$205K
- Sevag DemirjianCleveland$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.